Genomma Lab Internacional. de（GNML.F）株式概要Genomma Lab Internacional, S.A.B. de C.V.は、その子会社とともに、主にメキシコ国内および海外で医薬品およびパーソナルケア製品を提供している。 詳細GNML.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長2/6過去の実績2/6財務の健全性4/6配当金4/6報酬当社が推定した公正価値より64.6%で取引されている 収益は年間18.26%増加すると予測されています リスク分析株式の流動性は非常に低い 多額の負債を抱えている すべてのリスクチェックを見るGNML.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.0858.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2b23b2016201920222025202620282031Revenue Mex$23.5bEarnings Mex$2.2bAdvancedSet Fair ValueView all narrativesGenomma Lab Internacional, S.A.B. de C.V. 競合他社Pacira BioSciencesSymbol: NasdaqGS:PCRXMarket cap: US$923.9mAmphastar PharmaceuticalsSymbol: NasdaqGS:AMPHMarket cap: US$800.7mCollegium PharmaceuticalSymbol: NasdaqGS:COLLMarket cap: US$1.1bTheravance BiopharmaSymbol: NasdaqGM:TBPHMarket cap: US$842.4m価格と性能株価の高値、安値、推移の概要Genomma Lab Internacional. de過去の株価現在の株価Mex$1.0852週高値Mex$1.1752週安値Mex$0.91ベータ0.171ヶ月の変化0%3ヶ月変化n/a1年変化-0.92%3年間の変化31.09%5年間の変化4.85%IPOからの変化-44.62%最新ニュースお知らせ • Apr 14+ 1 more updateGenomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexicoお知らせ • Jan 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 25, 2026Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026お知らせ • Dec 09Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company presented a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on December 23, 2025. This amount per share is based on the total LABB shares currently outstanding.お知らせ • Oct 09Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 22, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025お知らせ • Jun 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 23, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025お知らせ • Jun 24Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on July 1st, 2025. This amount per share is based on the total LABB shares currently outstanding. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.最新情報をもっと見るRecent updatesお知らせ • Apr 14+ 1 more updateGenomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexicoお知らせ • Jan 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 25, 2026Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026お知らせ • Dec 09Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company presented a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on December 23, 2025. This amount per share is based on the total LABB shares currently outstanding.お知らせ • Oct 09Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 22, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025お知らせ • Jun 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 23, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025お知らせ • Jun 24Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on July 1st, 2025. This amount per share is based on the total LABB shares currently outstanding. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.お知らせ • Apr 08Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexicoお知らせ • Apr 01Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 30, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2025 results After-Market on Apr 30, 2025お知らせ • Mar 07Genomma Lab Internacional Announces Eleventh Cash Dividend PaymentGenomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on March 14, 2025. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024 ("AGSM"), have therefore deemed it appropriate to make this announced dividend payment. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.お知らせ • Feb 11Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 26, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2024 results at 3:00 PM, Central Standard Time on Feb 26, 2025お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 23, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024お知らせ • Oct 03Genomma Lab Pharma Manufacturing Facility Receives Pending GMP Certification for the Mexican Market from the Mexican Ministry of Health's Federal CommitteeGenomma Lab Internacional, S.A.B. de C.V. announced that it has received Good Manufacturing Practices ("GMP") certification from the Mexican Ministry of Health's Federal Committee for Protection from Sanitary Risks for its oral liquid, topical liquid and tablet coating manufacturing production at Genomma Lab's Medicinas y Medicamentos Nacionales, S.A. de C.V. manufacturing facility in the State of Mexico.お知らせ • Jul 04Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024お知らせ • Jun 16Genomma Lab Internacional, S.A.B. De C.V. Declares Cash DividendGenomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on June 21, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024, have therefore deemed it appropriate to make this announced dividend payment.お知らせ • Apr 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 24, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024お知らせ • Mar 14Genomma Lab Internacional, S.A.B. De C.V. Declares Cash DividendGenomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00 payable to shareholders of record of the applicable circulating shares at the close of business on March 25, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 28, 2023 (AGSM), have therefore deemed it appropriate to make this seventh announced dividend payment.お知らせ • Jan 24Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 21, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2023 results After-Market on Feb 21, 2024お知らせ • Dec 14Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend PaymentGenomma Lab Internacional, S.A.B. de C.V. (Genomma Lab) informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00, payable to shareholders of record of the applicable circulating shares at the close of business on December 27, 2023.お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 25, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2023 results After-Market on Oct 25, 2023お知らせ • Jul 06Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023お知らせ • Jan 31Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 22, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2022 results After-Market on Feb 22, 2023株主還元GNML.FUS PharmaceuticalsUS 市場7D0%4.9%1.0%1Y-0.9%44.2%28.7%株主還元を見る業界別リターン: GNML.F過去 1 年間で44.2 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: GNML.Fは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is GNML.F's price volatile compared to industry and market?GNML.F volatilityGNML.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: GNML.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のGNML.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19961,465Juan Marco Sparvieriwww.genommalab.comGenomma Lab Internacional, S.A.B. de C.V.は、その子会社とともに、主にメキシコ国内および海外で医薬品およびパーソナルケア製品を提供している。同社は、抗ニキビ製品、自己診断薬、抗菌剤、傷ついた肌のキメを整えるクリーム、シャンプー、フケ用シャンプー、石鹸、カミソリ、脱毛を防ぐ製品、筋肉痛用軟膏、大腸炎を緩和する抗真菌剤、大腸炎を緩和する抗真菌剤、筋肉痛用軟膏のカテゴリーで様々なブランド製品を開発、販売、マーケティングしている、大腸炎緩和のための抗真菌剤、ストレス対策製品、しわ防止剤、制酸剤、抗潰瘍剤、抗インフルエンザ剤、保護・改善製品、痔治療剤、静脈瘤治療剤、変形性関節症治療剤、眼科治療剤、乳児栄養剤など。Genomma Lab Internacional, S.A.B. de C.V.は1996年に設立され、メキシコのメキシコシティに本社を置いている。もっと見るGenomma Lab Internacional, S.A.B. de C.V. 基礎のまとめGenomma Lab Internacional. de の収益と売上を時価総額と比較するとどうか。GNML.F 基礎統計学時価総額US$878.74m収益（TTM）US$92.58m売上高(TTM)US$1.00b9.5xPER（株価収益率0.9xP/SレシオGNML.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計GNML.F 損益計算書（TTM）収益Mex$17.33b売上原価Mex$6.41b売上総利益Mex$10.91bその他の費用Mex$9.31b収益Mex$1.60b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）1.64グロス・マージン62.98%純利益率9.25%有利子負債／自己資本比率68.8%GNML.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金5.1%現在の配当利回り37%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 18:23終値2026/04/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genomma Lab Internacional, S.A.B. de C.V. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Antonio Hernandez Velez LeijaActinver Case de Bolsa, S.A. de C.V.Benjamin TheurerBarclaysRobert Ford AguilarBofA Global Research10 その他のアナリストを表示
お知らせ • Apr 14+ 1 more updateGenomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexico
お知らせ • Jan 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 25, 2026Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026
お知らせ • Dec 09Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company presented a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on December 23, 2025. This amount per share is based on the total LABB shares currently outstanding.
お知らせ • Oct 09Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 22, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
お知らせ • Jun 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 23, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025
お知らせ • Jun 24Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on July 1st, 2025. This amount per share is based on the total LABB shares currently outstanding. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.
お知らせ • Apr 14+ 1 more updateGenomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexico
お知らせ • Jan 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 25, 2026Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026
お知らせ • Dec 09Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company presented a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on December 23, 2025. This amount per share is based on the total LABB shares currently outstanding.
お知らせ • Oct 09Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 22, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
お知らせ • Jun 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 23, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025
お知らせ • Jun 24Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on July 1st, 2025. This amount per share is based on the total LABB shares currently outstanding. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.
お知らせ • Apr 08Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexico
お知らせ • Apr 01Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 30, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2025 results After-Market on Apr 30, 2025
お知らせ • Mar 07Genomma Lab Internacional Announces Eleventh Cash Dividend PaymentGenomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on March 14, 2025. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024 ("AGSM"), have therefore deemed it appropriate to make this announced dividend payment. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.
お知らせ • Feb 11Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 26, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2024 results at 3:00 PM, Central Standard Time on Feb 26, 2025
お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 23, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024
お知らせ • Oct 03Genomma Lab Pharma Manufacturing Facility Receives Pending GMP Certification for the Mexican Market from the Mexican Ministry of Health's Federal CommitteeGenomma Lab Internacional, S.A.B. de C.V. announced that it has received Good Manufacturing Practices ("GMP") certification from the Mexican Ministry of Health's Federal Committee for Protection from Sanitary Risks for its oral liquid, topical liquid and tablet coating manufacturing production at Genomma Lab's Medicinas y Medicamentos Nacionales, S.A. de C.V. manufacturing facility in the State of Mexico.
お知らせ • Jul 04Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024
お知らせ • Jun 16Genomma Lab Internacional, S.A.B. De C.V. Declares Cash DividendGenomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on June 21, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024, have therefore deemed it appropriate to make this announced dividend payment.
お知らせ • Apr 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 24, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024
お知らせ • Mar 14Genomma Lab Internacional, S.A.B. De C.V. Declares Cash DividendGenomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00 payable to shareholders of record of the applicable circulating shares at the close of business on March 25, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 28, 2023 (AGSM), have therefore deemed it appropriate to make this seventh announced dividend payment.
お知らせ • Jan 24Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 21, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2023 results After-Market on Feb 21, 2024
お知らせ • Dec 14Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend PaymentGenomma Lab Internacional, S.A.B. de C.V. (Genomma Lab) informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00, payable to shareholders of record of the applicable circulating shares at the close of business on December 27, 2023.
お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 25, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2023 results After-Market on Oct 25, 2023
お知らせ • Jul 06Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023
お知らせ • Jan 31Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 22, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2022 results After-Market on Feb 22, 2023
